Given that transcriptional dysregulation typifies the biology of Ewing sarcoma, we first evaluated the anti-tumor effect of transcription inhibition in Ewing sarcoma cells by testing THZ1, which is a newly developed covalent inhibitor of cyclin-dependent kinase 7 (CDK7). The gene discussed is CDK7; the disease is neoplasm.